Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|October 27, 2019
A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)Hajime Asahina, Satoshi Oizumi, Kei Takamura, et al.
The Oncologist|May 10, 2019
Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702)Megumi Furuta, Jun Sakakibara-Konishi, Hajime Kikuchi, et al.
The Lancet. Healthy Longevity|September 13, 2022
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trialYoshihito Kogure, Shunichiro Iwasawa, Hideo Saka, et al.
Scientific Reports|December 1, 2021
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)Gaku Yamamoto, Hajime Asahina, Osamu Honjo, et al.
Heliyon|July 21, 2020
Detection of somatic <i>TP53</i> mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survivalHiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, et al.
The New England Journal of Medicine|June 25, 2010
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRMakoto Maemondo, Akira Inoue, Kunihiko Kobayashi, et al.
Respiratory Investigation|March 19, 2025
Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancerDaisuke Morinaga, Kana Hashimoto, Hajime Asahina, et al.
JTO Clinical and Research Reports|October 15, 2024
Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)Kana Hashimoto, Daisuke Morinaga, Hajime Asahina, et al.
The European Respiratory Journal|April 1, 2022
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trialKohei Otsubo, Junji Kishimoto, Masahiko Ando, et al.
Oncoimmunology|September 23, 2021
Prognostic significance of OX40<sup>+</sup> lymphocytes in tumor stroma of surgically resected small-cell lung cancerHiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, et al.
Pageof 12